Top-News
Gesundheitswesen USA

Veracyte News

Aktie
WKN:  A1W7EA ISIN:  US92337F1075 US-Symbol:  VCYT
20,80 €
-0,40 €
-1,89%
14.05.24 13:27:39
Handeln Depot/Watchlist
Aktienanzahl *
75,07 Mio.
Marktkapitalisierung *
1,58 Mrd. €
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 04.03.2024

Veracyte News

31.05.23 - PR Newswire
Big Developments in Cancer Treatments set for Upcoming ASCO 2023 Annual Meeting in June
Big Developments in Cancer Treatments set for Upcoming ASCO 2023 Annual Meeting in June PR Newswire
31.05.23 - PR Newswire
Big Developments in Cancer Treatments set for Upcoming ASCO 2023 Annual Meeting in June
Big Developments in Cancer Treatments set for Upcoming ASCO 2023 Annual Meeting in June PR Newswire
19.09.17 - PR Newswire
Awareness Campaign Takes Lung Cancer Risk Head-On, Asking North Carolinians To Screen Together
Awareness Campaign Takes Lung Cancer Risk Head-On, Asking North Carolinians To Screen Together Veracyte, Inc. and the Lung Cancer Initiative Partner to Launch New Pilot ...
27.06.17 - PR Newswire
Veracyte Announces Publication of Study Supporting the Development of Envisia™ Genomic Classifier for IPF in Annals of the American Thoracic Society
Veracyte Announces Publication of Study Supporting the Development of Envisia™ Genomic Classifier for IPF in Annals of the American Thoracic Society PR Newswire
26.06.17 - PR Newswire
Veracyte Named a San Francisco Bay Area "Top Workplace" For Fourth Consecutive Year
Veracyte Named a San Francisco Bay Area "Top Workplace" For Fourth Consecutive Year PR Newswire
01.06.17 - PR Newswire
Veracyte to Present at William Blair 2017 Growth Stock Conference
Veracyte to Present at William Blair 2017 Growth Stock Conference PR Newswire
23.05.17 - PR Newswire
Veracyte Announces Clinical Validation Data Demonstrating Envisia™ Genomic Classifier's Performance in Improving Idiopathic Pulmonary Fibrosis Diagnosis Presented at ATS 2017
Veracyte Announces Clinical Validation Data Demonstrating Envisia™ Genomic Classifier's Performance in Improving Idiopathic Pulmonary Fibrosis Diagnosis Presented at ATS ...
18.05.17 - PR Newswire
Veracyte Announces Anthem Coverage for the Afirma® Gene Expression Classifier for Use in Thyroid Cancer Diagnosis
Veracyte Announces Anthem Coverage for the Afirma® Gene Expression Classifier for Use in Thyroid Cancer Diagnosis -- Every Major Health Plan in the U.S. Now Covers the ...
18.05.17 - PR Newswire
Veracyte Announces Anthem Coverage for the Afirma® Gene Expression Classifier for Use in Thyroid Cancer Diagnosis
Veracyte Announces Anthem Coverage for the Afirma® Gene Expression Classifier for Use in Thyroid Cancer Diagnosis -- Every Major Health Plan in the U.S. Now Covers the ...
11.05.17 - PR Newswire
Data Demonstrating Cost-Effectiveness of Veracyte's Percepta® Bronchial Genomic Classifier Published in "Journal of Thoracic Oncology"
Data Demonstrating Cost-​Effectiveness of Veracyte's Percepta® Bronchial Genomic Classifier Published in "Journal of Thoracic Oncology" -- Findings suggest that test's use ...
10.05.17 - PR Newswire
Veracyte Announces Six Studies Highlighting Value of Company's Genomic Classifiers in Lung Cancer and Idiopathic Pulmonary Fibrosis To Be Presented at ATS 2017
Veracyte Announces Six Studies Highlighting Value of Company's Genomic Classifiers in Lung Cancer and Idiopathic Pulmonary Fibrosis To Be Presented at ATS 2017 - New data ...
08.05.17 - PR Newswire
Data Presented at AACE 2017 Annual Meeting Demonstrate Long-Term Clinical Utility Of Veracyte's Afirma® Gene Expression Classifier in Thyroid Cancer Diagnosis
Data Presented at AACE 2017 Annual Meeting Demonstrate Long-Term Clinical Utility Of Veracyte's Afirma® Gene Expression Classifier in Thyroid Cancer Diagnosis Additional ...
04.05.17 - PR Newswire
Veracyte Announces Pivotal Clinical Validation Data for Next-Generation Afirma® Test To Help More Patients Avoid Unnecessary Surgery in Thyroid Cancer Diagnosis
Veracyte Announces Pivotal Clinical Validation Data for Next-​Generation Afirma® Test To Help More Patients Avoid Unnecessary Surgery in Thyroid Cancer Diagnosis Afirma ...
03.05.17 - PR Newswire
Veracyte Announces First Quarter 2017 Financial Results
Veracyte Announces First Quarter 2017 Financial Results PR Newswire
26.04.17 - PR Newswire
Veracyte Announces Multiple Studies Demonstrating Powerful Results from Afirma® Classifiers To Be Presented at the AACE 2017 Annual Meeting
Veracyte Announces Multiple Studies Demonstrating Powerful Results from Afirma® Classifiers To Be Presented at the AACE 2017 Annual Meeting Data from pivotal clinical ...
19.04.17 - PR Newswire
Veracyte to Host Conference Call and Webcast to Discuss First Quarter 2017 Financial Results on Wednesday, May 3, 2017
Veracyte to Host Conference Call and Webcast to Discuss First Quarter 2017 Financial Results on Wednesday, May 3, 2017 PR Newswire
03.04.17 - PR Newswire
Multiple Studies Presented at ENDO 2017 Support Use of Veracyte's Afirma® Gene Expression Classifier In Thyroid Cancer Diagnosis
Multiple Studies Presented at ENDO 2017 Support Use of Veracyte's Afirma® Gene Expression Classifier In Thyroid Cancer Diagnosis Veracyte Also Previews Next-​Generation ...
23.03.17 - PR Newswire
Veracyte Announces that Multiple Studies Supporting Clinical Utility of Its Afirma® Gene Expression Classifier To Be Presented at ENDO 2017
Veracyte Announces that Multiple Studies Supporting Clinical Utility of Its Afirma® Gene Expression Classifier To Be Presented at ENDO 2017 Company Will Also Preview Next-...
01.03.17 - PR Newswire
Veracyte Announces Fourth Quarter and Full-Year 2016 Financial Results, Provides 2017 Financial Outlook
Veracyte Announces Fourth Quarter and Full-Year 2016 Financial Results, Provides 2017 Financial Outlook PR Newswire
28.02.17 - PR Newswire
Veracyte Announces Executive Promotions
Veracyte Announces Executive Promotions Christopher M. Hall Appointed President and COO; John W. Hanna Named Chief Commercial Officer PR Newswire

Newssuche

Videos

newspaper
17.05.24 +7,67%
Technical Trading: Gold Long-​Chance
Gold Long Typ: Turbo Open End WKN: VD1G7Y Hebel: 10 Laufzeit: OpenEnd Einstieg: Market ... Mehr »